Ambrx Biopharma Inc.
NYSE: AMAM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel J. O'Connor
- Employees
- 87
- Headquarters
- La Jolla, United States
- IPO year
- 2023
- Market cap
- $1.8B
- Website
- https://ambrx.com
Loading AMAM…
Loading profile data…Frequently asked questions about AMAM
What does Ambrx Biopharma Inc. (AMAM) do?
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which i...
Where does AMAM trade?
Ambrx Biopharma Inc. (AMAM) trades on the New York Stock Exchange.
What sector is AMAM in?
Ambrx Biopharma Inc. (AMAM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ambrx Biopharma Inc.?
Daniel J. O'Connor is the chief executive officer of Ambrx Biopharma Inc. (AMAM).
Where is Ambrx Biopharma Inc. headquartered?
Ambrx Biopharma Inc. is headquartered in United States.
Does AMAM pay a dividend?
Ambrx Biopharma Inc. (AMAM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AMAM go public?
Ambrx Biopharma Inc. (AMAM) completed its initial public offering in 2023.